HHS Opioid Crisis Statistics

The last week of the month was always the hardest. That’s when Medicaid coverage gaps tend to bite — when prior authorizations expire and the pharmacy holds the prescription until someone picks up the phone. For people in medication-assisted treatment for opioid use disorder, that gap isn’t an administrative inconvenience. It is a clinical event. The brain, recalibrated around a daily dose of buprenorphine, doesn’t wait for the paperwork.

But the insurance shuffle STAT News documented in April 2026 — formulary restrictions, sudden prior authorization requirements, premium hikes for low-income enrollees — is only part of the system’s failure to hold. The larger and more disturbing part arrived in a federal courthouse in Kentucky, on June 8, when ProPublica and the Lexington Herald-Leader published a two-year investigation into Addiction Recovery Care, LLC, the company that once operated more than 40 treatment facilities in the state and controlled, at peak, approximately 67% of all addiction treatment beds in Kentucky.

The charges against former CEO Tim Robinson: attempting to resell millions in tax credits. The FBI whistleblower allegation, filed in 2023: billing Medicaid for group “psychoeducation” sessions that didn’t meet the standards of evidence-based care. The numbers: $1.7 billion billed to the state across five years. $377 million paid by Medicaid. And behind those numbers, tens of thousands of people who walked into ARC facilities believing, because they had to believe, that what happened inside those rooms would help them stay alive.

The Therapeutic Relationship Is Not Incidental to Recovery — It Is Recovery

Here is what the research says about what makes addiction treatment work, when it works. It is not primarily the building or the bed or even, in many cases, the medication — though medication-assisted treatment for opioid use disorder is the gold standard, supported by decades of evidence and dramatically outperforming abstinence-only approaches. What the research consistently finds, across modalities and populations, is that the quality of the therapeutic relationship — between the person seeking help and the person or system providing it — is one of the strongest predictors of engagement, retention, and outcome.

That relationship depends on trust. And trust depends on the therapeutic encounter being real.

When a company bills Medicaid for group sessions that function primarily as billing events rather than therapeutic ones, the harm isn’t just to the government’s wallet. The harm is to that relationship. Patients who attend sessions where the facilitator is running out the clock, where the content is drawn from a template designed to justify a billing code rather than to move anyone anywhere, learn something about the recovery ecosystem that is very hard to unlearn: it’s possible to be processed rather than helped. It’s possible for the whole apparatus to exist for reasons other than your survival.

This is not a minor psychological complication. For people with substance use disorders, who often arrive at treatment carrying decades of evidence that systems cannot be trusted — systems that criminalized their use, systems that denied their insurance claims, systems that told them addiction was a moral failure — discovering that the treatment facility itself was running a scheme is a confirmation of the worst thing they already believed. The therapeutic rupture here isn’t just interpersonal. It’s epistemological.

67% Is Not a Market Share. It’s a Monopoly on Lifelines.

To understand what ARC’s dominance meant for Kentucky patients, you have to understand what it means to have nowhere else to go.

SAMHSA’s 2023 National Survey on Drug Use and Health found that roughly 48.5 million Americans aged 12 and older had a substance use disorder in the prior year. Of those, approximately 15% received any form of treatment. The gap isn’t primarily a gap in desire to get help. It’s a gap in access — and access in rural and semi-rural states like Kentucky is especially constrained. There aren’t many options. When one company controls most of the options in a state, the normal market correctives don’t apply. A patient can’t take their business elsewhere if “elsewhere” doesn’t exist within a distance their transportation situation can reach.

It’s a gap in access — and access in rural and semi-rural states like Kentucky is especially constrained.

ARC understood this. The company grew aggressively through the opioid crisis years, acquiring facilities and opening new ones in communities where federal and state settlement dollars were flowing and demand was acute and competition was thin. Between 2019 and 2024, ARC billed the state $1.7 billion — not a misprint, billion — and received $377 million in Medicaid reimbursements. The whistleblower complaint filed by an FBI agent in 2023 alleged that a significant portion of this billing was for “psychoeducation” sessions that looked, on paper, like group therapy but functioned, in practice, as something closer to group attendance.

“Psychoeducation” is a legitimate modality. It involves structured education about the nature of addiction, the neurological mechanisms of dependence, coping strategies, and relapse prevention. Delivered well, by a trained clinician, it can be genuinely useful, particularly as a complement to individual therapy and medication. Delivered as a billing mechanism — scheduled to maximize reimbursable hours rather than therapeutic value, facilitated by undertrained staff running from a script — it is something else entirely. It is the form of treatment without the substance of it.

What the Evidence Says About What Works — and What Doesn’t

This distinction matters because of what the science tells us about recovery.

The most robust evidence in addiction medicine points to specific interventions that work: medication-assisted treatment with buprenorphine or methadone for opioid use disorder; contingency management for stimulant use disorders; cognitive-behavioral therapy delivered with fidelity to the evidence base; motivational interviewing as a foundational engagement technique. These interventions are effective because they address the specific neurological and psychological mechanisms of addiction — the dopaminergic dysregulation, the negative reinforcement cycles, the distorted cognition and impaired executive function that maintain use even when someone desperately wants to stop.

Generic group sessions of uncertain content, held daily to generate reimbursable hours, are not in this category. They may provide social contact, which has value. They may expose people to peers who are also trying to stop, which has value. But they don’t substitute for individualized assessment, tailored treatment planning, medication when indicated, or genuine clinical skill. If the billing alleged in the ARC whistleblower complaint is accurate — and the charges against Robinson, though not directly about patient care, suggest a company culture oriented toward extracting revenue rather than delivering value — then a meaningful portion of what passed for treatment in Kentucky for years was noise dressed up as signal.

Maia Szalavitz, who has spent decades covering addiction science and the failures of the treatment industry, argued in a 2025 piece for Filter that the United States’ for-profit addiction treatment sector has never been subject to the kind of outcome accountability that every other branch of medicine takes for granted. No hospital can bill Medicare for cardiac surgeries that didn’t improve cardiac outcomes for 67% of a state’s patients without eventually being caught. The addiction treatment sector, she wrote, operates with “remarkably little oversight of whether what happens inside facilities actually helps the people who enter them.”

The ARC case is the inevitable result of that absence.

The System That Allowed ARC to Grow This Large Did Not Fail by Accident

Here is the uncomfortable structural argument that the ProPublica investigation forces into focus: the Kentucky Medicaid system paid $377 million to a company whose billing practices are now under federal scrutiny. That money went somewhere. It went to executive compensation, to real estate, to the business of growing a treatment company in a market starved of oversight. It did not go, or did not go fully, to the people those bills claimed it was serving.

This is not a story about one bad actor. Tim Robinson may face personal consequences. But the conditions that allowed ARC to reach 67% market share in treatment beds — the underfunded oversight apparatus, the fee-for-service billing model that rewards volume over outcome, the desperation of communities with few alternatives, the political difficulty of regulating an industry that presents itself as fighting the overdose crisis — those conditions don’t change when one company’s CEO is charged with reselling tax credits.

Kentucky is not unique. The same dynamics play out in other states with thin provider markets and high treatment need: Ohio, West Virginia, rural California, large swaths of the Southwest. The for-profit treatment sector has consolidated significantly over the last decade, and consolidation concentrates risk. When one company fails — through fraud, through bankruptcy, through regulatory action — the patients it was serving have nowhere to go. This is not an abstraction. People lose their bed. They lose their medication management. They lose continuity of care in the moment when continuity matters most.

When one company fails — through fraud, through bankruptcy, through regulatory action — the patients it was serving have nowhere to go.

There Are People Still Inside Those Rooms

The ARC story broke on June 8. The facilities are, as of this writing, still operating. The people inside them did not get to pause their recovery while the legal proceedings sorted themselves out. They showed up the next morning to a program under federal scrutiny, many of them without the context to know what the investigation means, most of them focused on the immediate and overwhelming work of not using.

Whatever the outcome of the Robinson charges, whatever Medicaid eventually claws back or doesn’t, those people deserve a system that takes their care seriously. That means outcome-based contracting rather than pure fee-for-service billing. It means licensing requirements for group facilitators that actually reflect the evidence base. It means anti-monopoly attention to treatment provider markets, especially in rural areas where one company can come to dominate an entire state’s access infrastructure. It means treating addiction treatment as medicine — which means holding it to medical standards of accountability — rather than as a social service that can be delivered at scale without rigorous quality monitoring.

Forty years of peer-reviewed research has told us what works. What we’ve never had is a payment and oversight system willing to insist on it.

The people at ARC’s facilities this morning deserve that insistence. They have already placed enormous trust in a system that, in Kentucky at least, appears to have been selling them something less than what it promised.

That is the question the ARC case poses to every state that oversees an addiction treatment market, and to every patient in one: Who is watching the people who say they’ll save you?

And right now, the honest answer is: not enough people, not closely enough, and not with the right incentives to care what they find.